Prospective study designed to assess the immunological effect of a specific B. infantis strain on the incidence of atopic dermatitis.
Infinant Health, Inc, a company focused on improving infant health through the gut microbiome, today announced the enrollment of the final participant in a study focused on the infant microbiome and immune health.
The study, which has been conducted in Finland by Johnson & Johnson Consumer Inc. in collaboration with Infinant Health, investigates the clinical and immunological effects of supplementation with a live B. infantis strain in healthy breastfed infants.
“Infinant Health is committed to improving the lifelong health of all infants through life-changing science and innovation to ensure all babies have a vital start to life,” said Infinant Health CEO, Mike Johnson. ” Studying the infant microbiome to inform potential solutions for immune health is critical as we look to provide a healthier future for all children.”
The study has enrolled over 270 infants in Finland overcoming significant pandemic-related recruitment challenges and will assess clinical and immunological outcomes of each subject over the course of 2 years.
“As a prospective placebo-controlled randomized study, this is an important step towards validating the direct impact of B. infantis on the infant microbiome and its relationship to overall immune health,” said Infinant Health Global Medical & Scientific Advisor, Karl Sylvester.
To learn more about the study, visit the following link at ClinicalTrials.gov.
Related content in In The Press
